| Symbol | PLLWF |
|---|---|
| Name | POLAREAN IMAGING LTD. |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | W1W 8DH United Kingdom ENG 27-28 Eastcastle Street |
| Telephone | 919-206-7900 |
| Fax | — |
| — | |
| Website | http://www.polarean.com |
| Incorporation | GB |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | NOT AVAILABLE |
| Reporting Status | International Reporting: Foreign Issuer - Not Listed on Foreign Exchange |
| CIK | — |
| Description | The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream. Additional info from OTC: The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarized Xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream. |
No news found.